Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 3092Triple Negative Breast Neoplasms 504Ovarian Neoplasms 224Colorectal Neoplasms 189Carcinoma, Non-Small-Cell Lung 187Prostatic Neoplasms 180Neoplasms 171Lung Neoplasms 164Neoplasm Metastasis 159Melanoma 116Stomach Neoplasms 113Pancreatic Neoplasms 111Endometrial Neoplasms 105Uterine Cervical Neoplasms 93Squamous Cell Carcinoma of Head and Neck 87Head and Neck Neoplasms 81Colonic Neoplasms 81Carcinoma, Intraductal, Noninfiltrating 80Sarcoma 63Breast Carcinoma In Situ 61Carcinoma, Renal Cell 60Urinary Bladder Neoplasms 59Esophageal Neoplasms 58Motor Activity 57Brain Neoplasms 50Lymphedema 42Breast Cancer Female 40Advanced Breast Cancer 40Liver Neoplasms 39Gastrointestinal Neoplasms 38

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian × Breast × 1 year × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡